Abstract
Recently, the combining of different drugs has greatly improved response and survival rates in gynecological malignancies. Results are however far from being satisfactory. Treatments used in case of advanced or recurrent disease offer limited results in terms of long-term responses. The urgent need for new and more effective treatments has prompted researchers to investigate and propose new therapeutic strategies. One of the most interesting approaches that are being explored is constituted by immunotherapy. Currently, immunotherapeutic strategies include vaccination with peptide, viral vectors, carbohydrates and antiidiotypic antibodies. In addition, cell based immunotherapy has been adopted in vitro activated lymphocytes and dendritic cells. Most experience has been acquired in ovarian cancer and cervical cancer. Little has been investigated in endometrial and rare gynecologic neoplasms.
The clinical experiences and results achieved with immunotherapy in this setting of patients have been reviewed and the future avenues that are currently being explored have also been discussed.
Keywords: Anti-idiotypic antibody, cancer vaccine, cervical cancer, dendritic cells, gynecological cancer, immunotherapy, lymphocytes, ovarian cancer
Current Molecular Medicine
Title:Past, Present and Future Strategies of Immunotherapy in Gynecological Malignancies
Volume: 13 Issue: 4
Author(s): F. Bellati, C. Napoletano, I. Ruscito, V. Visconti, M. Antonilli, M.L. Gasparri, I.G. Zizzari, H. Rahimi, I. Palaia, A. Rughetti, P. Benedetti Panici and M. Nuti
Affiliation:
Keywords: Anti-idiotypic antibody, cancer vaccine, cervical cancer, dendritic cells, gynecological cancer, immunotherapy, lymphocytes, ovarian cancer
Abstract: Recently, the combining of different drugs has greatly improved response and survival rates in gynecological malignancies. Results are however far from being satisfactory. Treatments used in case of advanced or recurrent disease offer limited results in terms of long-term responses. The urgent need for new and more effective treatments has prompted researchers to investigate and propose new therapeutic strategies. One of the most interesting approaches that are being explored is constituted by immunotherapy. Currently, immunotherapeutic strategies include vaccination with peptide, viral vectors, carbohydrates and antiidiotypic antibodies. In addition, cell based immunotherapy has been adopted in vitro activated lymphocytes and dendritic cells. Most experience has been acquired in ovarian cancer and cervical cancer. Little has been investigated in endometrial and rare gynecologic neoplasms.
The clinical experiences and results achieved with immunotherapy in this setting of patients have been reviewed and the future avenues that are currently being explored have also been discussed.
Export Options
About this article
Cite this article as:
Bellati F., Napoletano C., Ruscito I., Visconti V., Antonilli M., Gasparri M.L., Zizzari I.G., Rahimi H., Palaia I., Rughetti A., Benedetti Panici P. and Nuti M., Past, Present and Future Strategies of Immunotherapy in Gynecological Malignancies, Current Molecular Medicine 2013; 13 (4) . https://dx.doi.org/10.2174/1566524011313040014
DOI https://dx.doi.org/10.2174/1566524011313040014 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Piceatannol Modulates Lung Epithelial Cellular Responses to Pseudomonas aeruginosa
Inflammation & Allergy - Drug Targets (Discontinued) Disorders of Sex Development: A Review
Current Women`s Health Reviews Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases
Current Pharmaceutical Design Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
Current Cancer Therapy Reviews Microemulsions for Colorectal Cancer Treatments. General Considerations and Formulation of Methotrexate
Mini-Reviews in Medicinal Chemistry Evolution and Pathogenesis of Oncoviruses Associated with Head and Neck Cancer: History and Current Concepts
Recent Patents on Biomarkers Antiinflammatory Activity of Melatonin in Central Nervous System
Current Neuropharmacology Lipid Based Nanoparticles as Inherent Reversing Agents of Multidrug Resistance in Cancer
Current Pharmaceutical Design Sesamol Induces Apoptosis by Altering Expression of Bcl-2 and Bax Proteins and Modifies Skin Tumor Development in Balb/c Mice
Anti-Cancer Agents in Medicinal Chemistry Antitumoral Potential of Snake Venom Phospholipases A2 and Synthetic Peptides
Current Pharmaceutical Biotechnology Anti-Mycobacterial Peroxides: A New Class of Agents for Development Against Tuberculosis
Medicinal Chemistry Recent Advances in Understanding and Exploiting the Activation of Anthracyclines by Formaldehyde
Current Medicinal Chemistry - Anti-Cancer Agents Nanoformulations of Coumarins and the Hybrid Molecules of Coumarins with Potential Anticancer Effects
Anti-Cancer Agents in Medicinal Chemistry Antiviral Effects of Saffron and its Major Ingredients
Current Drug Delivery Advances in Photodynamic Therapy Assisted by Electroporation
Current Drug Metabolism Decoding the Emerging Patterns Exhibited in Non-coding RNAs Characteristic of Lung Cancer with Regard to Their Clinical Significance
Current Genomics Understanding Abnormal c-JNK/p38MAPK Signaling in Amyotrophic Lateral Sclerosis: Potential Drug Targets and Influences on Neurological Disorders
CNS & Neurological Disorders - Drug Targets Molecular Targeted Approaches to Cancer Therapy and Prevention Using Chalcones
Current Cancer Drug Targets Recent Syntheses and Biological Activity of Lentiginosine and its Analogues
Current Topics in Medicinal Chemistry Role of Tumor Microenvironment in Cancer Stem Cells Resistance to Radiotherapy
Current Cancer Drug Targets